DJ Bioanalytical Systems to Expand Service Offerings

By Michael Dabaie

Bioanalytical Systems Inc. said Wednesday it plans to expand its service offerings to add cardiovascular safety pharmacology capabilities.

The provider of nonclinical and analytical contract research services, which does business as Inotiv, said it plans to add cardiovascular safety pharmacology capabilities to its existing capabilities for respiratory and central nervous system safety pharmacology.

Safety pharmacology evaluations are critical for assessing the effect of drug candidates, the company said.

Inotiv said that by summer 2021 it expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and central nervous system functions as standalone safety pharmacology packages or as part of a full investigational new drug/clinical trial application program.

The company previously relied on subcontractors for these cardiovascular assessments.

"Over the past year, we've made significant investments towards reducing our subcontracted and outsourced work," said Chief Executive Robert Leasure Jr. "This is a continuation of that strategy that we believe will allow us to improve speed and control quality of services while also enhancing margins."

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

March 17, 2021 09:08 ET (13:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.